Antiproliferative And Antiangiogenic Effects Of The Benzophenanthridine Alkaloid Sanguinarine In Melanoma

Ilaria de Stefano, Giuseppina Raspaglio, Gian Franco Zannoni, Daniele Travaglia, Maria Grazia Prisco, Marco Mosca, Cristiano Ferlini, Giovanni Scambia, Daniela Gallo

► To cite this version:

Ilaria de Stefano, Giuseppina Raspaglio, Gian Franco Zannoni, Daniele Travaglia, Maria Grazia Prisco, et al.. Antiproliferative And Antiangiogenic Effects Of The Benzophenanthridine Alkaloid Sanguinarine In Melanoma. *Biochemical Pharmacology*, 2009, 78 (11), pp.1374. 10.1016/j.bcp.2009.07.011 . hal-00524466

HAL Id: hal-00524466

<https://hal.science/hal-00524466>

Submitted on 8 Oct 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Antiproliferative And Antiangiogenic Effects Of The Benzophenanthridine Alkaloid Sanguinarine In Melanoma

Authors: Ilaria De Stefano, Giuseppina Raspaglio, Gian Franco Zannoni, Daniele Travaglia, Maria Grazia Prisco, Marco Mosca, Cristiano Ferlini, Giovanni Scambia, Daniela Gallo

PII: S0006-2952(09)00643-1
DOI: doi:10.1016/j.bcp.2009.07.011
Reference: BCP 10268

To appear in: *BCP*

Received date: 8-6-2009
Revised date: 16-7-2009
Accepted date: 17-7-2009

Please cite this article as: De Stefano I, Raspaglio G, Zannoni GF, Travaglia D, Prisco MG, Mosca M, Ferlini C, Scambia G, Gallo D, Antiproliferative And Antiangiogenic Effects Of The Benzophenanthridine Alkaloid Sanguinarine In Melanoma, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.07.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ANTIPROLIFERATIVE AND ANTIANGIOGENIC EFFECTS OF THE BENZOPHENANTHRIDINE ALKALOID SANGUINARINE IN MELANOMA

Ilaria De Stefano^{1*}, Giuseppina Raspaglio^{1*}, Gian Franco Zannoni², Daniele Travaglia¹, Maria
Grazia Prisco¹, Marco Mosca¹, Cristiano Ferlini¹, Giovanni Scambia¹, and Daniela Gallo¹.

¹Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic
University of the Sacred Heart, Rome, Italy

²Department of Histopathology, Catholic University of the Sacred Heart, Rome, Italy

*These Authors equally contributed to this work.

Running title: Sanguinarine in melanoma

Correspondence to:

Dr. Daniela Gallo

Laboratory of Antineoplastic Pharmacology

Department of Obstetrics and Gynecology

Catholic University of the Sacred Heart, Rome, Italy

Largo A. Gemelli, 8 - 00168 - Rome - Italy

Tel +39 06 3013337

Fax. +39 06 35508736

e-mail: d.gallo@rm.unicatt.it

ABSTRACT

This study was aimed at evaluating the potential application of benzophenanthridine alkaloids, sanguinarine and chelitrine, in the therapy of melanoma cancer. *In vitro* antiproliferative activity of sanguinarine was higher than that of chelitrine against the B16 melanoma 4A5 cells. Both agents were able to produce DNA breaks, and the DNA unwinding assay showed that they act as DNA intercalating agents. Sanguinarine was selected for determination of its *in vivo* preclinical efficacy. Oral treatment with sanguinarine reduced the tumor burden in a transplantable murine tumor grown in a syngenic host (B16 melanoma 4A5 in C57BL/6 mice), and in a human tumor xenograft grown in immunodeficient mice (A375 human melanoma in athymic nude mice). In A375 tumors a significant decrease in the proliferation marker Ki67, and a reduction in the activated mitogen-activated protein kinases (p-p44/42 MAPK), and in protein kinase B (pAKT) were also observed. Three out of eleven A375-bearing treated mice were tumor-free at the end of treatment, and did not develop any tumor after a further, treatment-free, observation period of 60 days. Sanguinarine also showed a striking anti-angiogenic activity in mice. Data from the present study support the concept that sanguinarine can be effective in melanoma skin cancer.

Key words: sanguinarine, melanoma, angiogenesis, MAPK, mice

1. INTRODUCTION

Malignant melanoma is an aggressive, therapy-resistant malignancy of melanocytes. The incidence of melanoma has been steadily increasing worldwide, resulting in an increasing public health problem. In Europe, 26 368 males and 35 909 females are diagnosed each year with melanoma, and around 8 500 males and 8 000 females die because of it [1]. In the United States, about 62 480 cases of melanoma were expected to be diagnosed in 2008, with about 8 420 Americans dead from this cancer [2]. As with most malignant disorders, prognosis is highly dependent on the clinical stage (extent of tumor burden) at the time of diagnosis, and the patient's clinical stage at diagnosis dictates selection of therapy. If melanoma is diagnosed early it can be cured by surgical resection, and about 80% of cases undergo this treatment. However, metastatic malignant melanoma is largely refractory to existing therapies, and has a poor prognosis, with a median survival rate of 6 months, and a 5-year survival rate of less than 5% [3]. There are several approved postoperative adjuvant therapies for malignant melanoma [3, and references therein]. Interferon- α (IFN- α) is the most commonly used adjuvant immunotherapy for advanced melanoma, although its efficacy is still a matter of debate. High-dose interleukin-2 (IL-2) has also been approved, but response rates are low, and toxicity is a problem. Dacarbazine (DTIC) is the reference approved chemotherapeutic agent for the treatment of advanced melanoma, and drugs such as carmustine (BiCNU), paclitaxel (Taxol), temozolomide and cisplatin have shown single-agent activity in metastatic disease [4]. In addition, many different immunotherapies have been tested, but so far none of these approaches has reached regulatory approval [5]. Overall, despite decades of investigation, no systemic treatment that improves overall survival in patients with advanced metastatic melanoma has been developed, and new treatment options are urgently needed.

Natural products have long been a fertile source of cure for cancer, with plant-derived drugs becoming increasingly explored and integrated into chemotherapy strategies; there are at least

250,000 species of plants, out of which more than one thousand have been found to possess significant anticancer properties [6]. Recently, the benzophenanthridine alkaloids, which are mainly distributed in Papaveraceae (*Chelidonium majus*, *Macleaya cordata*, and *Sanguinaria canadensis* L), have been the focus of increasing attention for their anticancer activity [7-9]. Specifically, several studies have indicated that sanguinarine [13-methyl-(1,3)benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i] phenanthridinium], a compound endowed with antimicrobial, antioxidant, and anti-inflammatory properties [10, and the references therein], is able to inhibit the growth of various human cancer cell lines, at micromolar concentration, inducing a selective apoptotic response in cancer cells *versus* normal cells [7, 9, 11]. Notably, a recent study has also shown that sanguinarine reduces *in vitro* cell proliferation of K1375-M2, a very invasive melanoma cell line; Authors reported that sanguinarine acts as a DNA damaging agent, showing also collateral damage to mitochondrial bioenergetics, in a fashion similar to doxorubicin [12].

In the present study, we have explored the potential application of benzophenanthridine alkaloids sanguinarine and chelerritrine in the therapy of melanoma cancer. To this end, *in vitro* antiproliferative activity of the compounds was investigated, along with their mechanism of action; sanguinarine was selected for preclinical *in vivo* evaluations. Results obtained demonstrated that the antitumoral effect of sanguinarine relies on its activity on several critical steps in primary tumor progression, including cell proliferation and angiogenesis.

2. MATERIALS AND METHODS

2.1. Drugs and reagents

For *in vitro* studies, sanguinarine chloride and chelerritrine chloride (donated by INDENA Milan, Italy) were diluted in DMSO. Solutions were further diluted at each experimental day in order to achieve a 0.1% final DMSO concentration. All reagents were purchased from Sigma (Sigma- Chemical Co. St. Louis, Mo.), unless indicated.

2.2. Cell Lines

B16 melanoma 4A5 cells, a cell line derived from subcutaneously inoculated B16F0 tumors in C57BL/6 strain mouse, and A375 cells, derived from a 54 year old female with malignant melanoma, were purchased from the European Collection of Cell Cultures (ECACC, Salisbury, UK). Cells were grown in DMEM medium with 4500 mg/L glucose, supplemented with 10% fetal bovine serum, 1% non-essential amino acids mixture, 1% Kanamycin. Cells, propagated as a monolayer culture, were trypsinized twice weekly, and plated at a density of 10×10^4 cells per mL. All cultures were incubated at 37 °C under 5% CO₂ in a high humidity atmosphere.

2.3. Growth inhibition assay

B16 melanoma 4A5 cells were seeded (20 000 cells/well) in 96-well flat bottom plates (Viewplates, Perkin Elmer Life Science, Waltham, MA). After 24 hours, media were replaced and, after one washing, media containing the tested compounds were added. Three independent experiments were performed in quadruplicates. After 72 h of culture in the presence of the compounds, plates were harvested and the number of viable cells was estimated by dosing ATP, using the ATPlite kit (Perkin-Elmer Life Science), and the automated luminometer Topcount (Perkin-Elmer Life Science). For each compound a dose–response curve was plotted, and the IC₅₀ values were then calculated by fitting the concentration–effect curve data obtained in the three experiments with the sigmoid-Emax

model using nonlinear regression, weighted by the reciprocal of the square of the predicted effect [13].

2.4. *Single cell gel electrophoresis (Comet assay)*

Nuclei were isolated from B16 melanoma 4A5 cells by incubating whole cells in a buffer containing 5 mM MgCl₂, 1 mM EGTA, 1 mM KH₂PO₄, 150 mM NaCl, for 20 min on ice with gentle rocking. Plasma membrane disruption and nuclei integrity were checked under the microscope. Isolated nuclei were exposed to the drugs for 60 min. Drug-untreated or H₂O₂-treated (50 µM for 5 min on ice) samples were run as negative and positive controls for DNA damage, respectively. DNA breaks were detected as described [14]. The calculations of the %Tail DNA were carried out using the Kinetic Komet 5.0 software from Kinetic Imaging Ltd. (Liverpool, UK).

2.5. *Relaxation activity of Topoisomerase-I*

Topoisomerase-I (Topo-I) functional activity was assayed by relaxation of supercoiled plasmid DNA in a cell free system as described [14]. Images were acquired and quantified through the Phoretix 1D software package (Phoretix International Ltd, Newcastle, Tyne and Wear, UK).

2.6. *Measurement of DNA intercalation*

Intercalation was determined by the unwinding assay [15]. Supercoiled pBR322 DNA (Roche Diagnostics Corporation, Indianapolis, IN, USA) was relaxed with 300 U of Topo-I (Topogen, Port Orange, FL) (37 °C, 15 min) in Topo-I relaxation buffer (Topogen). To confirm full relaxation of DNA, one sample was terminated with SDS after 75 min. Inhibitors were added and the incubations were continued for another 60 min. The reaction was terminated by addition of 1% (w/v) SDS. After digestion with proteinase K, open circular and linear DNA were separated from intact supercoiled and relaxed form, by agarose gel electrophoresis in the presence of 1 µg/ml ethidium bromide, under the same conditions as for

the relaxation assay. The compounds were removed by extraction with chloroform/isoamyl alcohol (24:1), and topoisomers were separated on 1% agarose in Tris-Borate buffer. The gel was stained with ethidium bromide and acquired as described above.

2.7. *Animals*

Female C57BL/6, and female athymic mice [Athymic Nude-nu], 6 weeks old, were obtained from Charles River S.r.l. (Lecco, Italy), and housed under controlled conditions. The UKCCCR guidelines for the welfare of animals in experimental neoplasia were followed [16]. Studies were approved by the Animal Care and Use Committee of the Catholic University of the Sacred Heart (Rome, Italy), and by the Italian Ministry of Health.

2.8. *Tumor Growth*

On the day of inoculation, a suspension of B16 melanoma 4A5 (2×10^5) or A375 (5×10^6) cells was injected subcutaneously in C57BL/6 or athymic mice, respectively. Sanguinarine was dissolved in PEG 300: sterile water (1:2). Tumor-bearing mice received via gavage either 5 mg sanguinarine/kg/day or vehicle (n=10-12 mice/group), daily, week-end off. Dosage used in this study was selected on the basis of previous unpublished data showing that the Maximum Tolerated Dose following oral chronic administration is 5 mg/kg/day. Body weight and tumor dimensions were measured two times per week. Due to excessive tumor ulceration, all mice bearing B16 melanoma 4A5 tumors were sacrificed on day 18 of the study; athymic mice bearing A375 xenografts were sacrificed when tumor weight was in the range of 1300-1500 mg. At sacrifice, blood was collected and serum frozen at -20°C for analysis; all tumors were removed, and subsequently cut into two fragments: one-half of the tumor was snap-frozen in liquid nitrogen, before storage at -80°C for protein analysis, the other half was fixed in 10% formalin and subsequently dehydrated and blocked in paraffin.

2.9. Evaluation of anti-tumor activity

Tumor weight was calculated from two dimensional measurements (mm) [17]: Tumor weight = length x width²/ 2. The ratio between the mean tumor weight of treated mice and that of control mice x 100 (T/C%) was assessed on each day of measurement. Differences in efficacy between treatment groups were expressed as the percentage of maximum tumor weight inhibition (TWI %), calculated as follows: TWI % = 100 –T/C%. The optimum value for tumor weight inhibition obtained during the study was considered. In the A375 model, significant differences in tumor progression were evaluated by the Kaplan-Meier survival analysis followed by logrank test, using as end-point a tumor weight of 1000 mg.

2.10. Immunohistochemical analysis

Immunohistochemical analysis of monoclonal mouse anti-human Ki67 (M7240, DAKO Italia, Milano, IT) (1:50 dilution, 60 min, room temperature) was carried out on 3-μm thick paraffin sections as described [18]. Immunohistochemical scoring was determined without any knowledge of which group the mice belonged to. The number of positive (brown stained) cells was determined as a percentage of the total number of cells counted in 5 separate fields of 100 cells, in non necrotic areas of 8 tumor section, in each group.

2.11. Immunoblotting

Samples (80 μg aliquots as determined by the Bradford assay, Bio-Rad Laboratories, Inc., Hercules, CA) were separated on SDS-PAGE and immunoblot analyses were carried out as described [19]. Antibodies used included: rabbit anti-phospho-p44/42 mitogen-activated protein kinase (p-p44/42 MAPK) (Thr202/Tyr204), and anti-total-p44/42 MAP kinase (1:1000); rabbit anti-phospho-AKT (p-AKT) (Ser473), and anti-total-AKT (1:1000) (all from Cell Signaling Technology, Boston, MA); mouse anti-β-actina (1:4000). Protein level were quantified by densitometric analysis using the Scion Image Beta 4.02 software package (Scion Corporation, Frederick, MD, USA).

2.12. Angiogenesis Assay

The method described by Passaniti et al. [20] was used, with some modifications. Briefly, b-FGF (300 ng/ml) was incorporated into liquid Matrigel (12.5 mg/ml) and a plug of 0.45 ml Matrigel was injected subcutaneously into the ventral abdominal wall of each female athymic mice. Mice (10/group) received via gavage sanguinarine (5 mg/kg/day) or vehicle, daily, for 6 days from the day of Matrigel injection. At day 7, the pellet was removed, and the hemoglobin content was measured by the Drabkin's procedure (Drabkin reagent kit). Matrigel and basic Fibroblast Growth Factor (bFGF) were obtained from Becton Dickinson (Bedford, MA).

2.13. Statistical methods

Tumor weight data were analyzed by repeated-measures ANOVA, followed by the Bonferroni method as post-test. To determine significant differences in tumor progression between groups, the Kaplan-Meier survival analysis was used, followed by logrank test (A375 only). The remaining data were analyzed by the unpaired t test. Statistical analysis was carried out with GraphPad Prism5 Software (San Diego, CA, USA). $P < 0.05$ was used as the critical level of significance.

3. RESULTS

3.1. *In vitro* studies

The benzophenanthridine alkaloids sanguinarine and chelerritrine, tested in B16 melanoma 4A5 cell line, yielded IC₅₀ values of 1.96 ± 0.22 , and 2.9 ± 0.22 μ M respectively, following 72 hours of drug exposure; these results clearly pointed out that sanguinarine was more active than chelerritrine against melanoma cancer cells, and, for this reason, it was selected for subsequent *in vivo* investigations. A potential effect of drugs on the nuclear structure was assessed by Comet assay and results are shown in **Fig. 1A and B**: both compounds were able to induce DNA breaks, but the effect was greater upon sanguinarine treatment. Topo-I was then investigated as a possible target. A representative experiment is shown in **Fig. 2A**. Notably, both sanguinarine and chelerritrine were able to markedly inhibit the process of DNA relaxation. This result prompted us to investigate whether the substances under investigation, rather than a specific activity on Topo-I, were DNA intercalating agents. This hypothesis was tested through the DNA unwinding assay. Several topoisomers of a DNA plasmid are noticeable in normal isotonic buffers, but when an intercalating agent is added to DNA, the structure of DNA changes and the number of possible topoisomers decreases. Using again a p-Bluescript plasmid, and Ethidium Bromide as positive control, this assay clearly demonstrated that both the agents were able to intercalate into the DNA structure (**Fig. 2B**).

3.2. *In vivo* studies

3.2.1. *Antitumor efficacy*

In the first set of experiments, C57BL/6 female mice were injected s.c. with B16 melanoma 4A5 cells, a very aggressive syngenic tumor with a rapid growth rate, and treated orally with sanguinarine 5 mg/kg/day or vehicle, until the end of the study. Results showed a relevant therapeutic activity with suppression of tumor growth in comparison with control mice

($p < 0.01$, by repeated-measures ANOVA, followed by Bonferroni test, **Fig. 3A**). A TWI of 52% was recorded on day 18 of the study. Similar results were also obtained using A375, a tumor with a slower rate of *in vivo* growth; also in this case, sanguinarine-treated mice had a significant therapeutic effect, showing a significant tumor growth inhibition in comparison to control mice ($p < 0.05$, **Fig. 3C**). A TWI of 58% was recorded on day 60 of the study. In addition, results from the Kaplan- Meier analysis (**Fig. 3E**) showed that treatment significantly improved time to tumor progression versus control mice ($p < 0.05$), the end point criterion being tumors grown to 1000 mg. By day 77 of the study, there were three tumor-free mice; these mice were no longer dosed, showing no evidence of tumor after a further treatment-free observation period of 60 days (i.e. day 137 of the study). Body weight (**Fig. 3B and 3D**) and food consumption (data not shown) did not significantly differ among treatment groups in both studies, thus confirming the absence of drug toxicity at the selected dose level.

3.2.2. Effect on tumor proliferation

Proliferation of A375 cells significantly differed among groups (**Fig. 4A and B**). An average value of $66.0 \pm 5.1\%$ (mean $\pm$ SEM) Ki67 positive cells was recorded in control tumors. A reduction in proliferation was observed in animal receiving 5 mg/kg/day sanguinarine, the mean value of positive stained cells being $50.0 \pm 3.2\%$; this change reached statistical significance, with respect to controls ($p = 0.03$).

3.2.3. Effect on pMAPK/MAPK and pAKT/AKT levels in tumors

Representative immunoblots of the total and the phosphorylated forms of the proteins are shown in **Fig. 4C and 4E**. Results obtained showed that the ratio p-p44/42 MAPK/p44/42 MAPK was decreased in A375 tumors following treatment with 5 mg/kg/day sanguinarine, this change reaching statistical significance (**Fig. 4D**, $p = 0.04$ vs controls). Tumors from treated mice also tended to have a lower pAKT/AKT ratio compared to controls (**Fig. 4F**, $p = 0.07$).

3.2.4. Angiogenesis in vivo

Daily oral doses of 5 mg/kg sanguinarine for 6 days significantly reduced the angiogenic response induced by bFGF (**Fig. 5A and B**). The mean hemoglobin content of bFGF-containing pellets was significantly lower ($p = 0.02$) in sanguinarine-treated mice (0.05 ± 0.009 g/dl, mean $\pm$ SEM) than in vehicle-treated mice (0.11 ± 0.012 g/dl, mean $\pm$ SEM).

4. DISCUSSION

Experimental data from the present study support the concept that sanguinarine can be effective in melanoma skin cancer. During a cellular screening of benzophenanthridine alkaloids we found that the drug resulted more active than the analogous compound chelitrine against the murine cell line B16 melanoma 4A5, and that it mainly acts as an intercalating agent producing DNA breaks. This finding is in keeping with earlier data from Maiti and colleagues [21], showing that sanguinarine strongly interacts with DNA, binding, like ethidium bromide, by monofunctional mode of intercalation. Importantly, previous Authors have suggested that the cytotoxic and the DNA damaging effects of sanguinarine are selective against cancer cells as compared to normal cells [7, 22], a finding, however, not confirmed by other studies [23]. We did not evaluate the effects of sanguinarine on normal melanocytes in the present work; while not addressing safety issues at this time, we believe, however, that properly designed *in vitro* and *in vivo* experiments are needed to exploit the undesired toxic effect of this alkaloid to normal tissue. Indeed, toxicity is a crucial matter in the development of anticancer drugs, often derailing clinical trials.

The activity of sanguinarine in melanoma was then confirmed *in vivo*, against a transplantable murine tumor grown in a syngeneic host (B16 melanoma 4A5 in C57BL/6 mice), and against a human tumor xenograft grown in immunodeficient mice (A375 in athymic nude mice).

Because of an intact tumor host environment, the syngeneic transplantable mouse tumor model represents a valuable experimental model for the evaluation of therapies that require immune response, or that target specific components of blood vessels or the extracellular matrix. Conversely, the human xenograft tumor grown in nude mice exhibits a proliferative pattern with molecular and pathophysiological features similar to patient-tumor characteristics. In both experimental models, oral sanguinarine administration reduced by more than 50% tumor development, compared to controls. In A375 tumors, this result was

1 associated with a significant decrease in the proliferation marker Ki67, and with a reduction
2 in the activated MAPK and AKT. These latter findings are particularly important when
3
4 considering that the RAS/RAF/MEK/ERK (MAPK) and PI3K/AKT (AKT) signaling
5
6 pathways are constitutively activated through multiple mechanisms, and appear to play a
7
8 major role in melanoma development and progression, this implying that combined targeting
9
10 of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment [24].
11
12 Notably, 3 out of 11 A375-bearing treated mice were tumor-free at the end of treatment (i.e.
13
14 day 77 of the study), showing no evidence of tumor after a further, treatment-free, observation
15
16 period of 60 days. It is worthy to note that preliminary pharmacokinetics data obtained in our
17
18 laboratory indicated that within two hours following oral treatment with 5 mg/kg
19
20 sanguinarine, the compound achieved relevant levels in plasma and in B164A5 tumors
21
22 (unpublished data).
23
24

25
26
27 The antiproliferative activity of sanguinarine has been mainly attributed to its involvement on
28
29 critical molecular events regulating the cell cycle and the apoptotic machinery [7, 9, 25, 26],
30
31 yet its observed therapeutic effect cannot be ascribed solely to a direct antiproliferative
32
33 activity, as indicated by data from the present study, showing that the role of the alkaloid in
34
35 tumor suppression is more complex than that of merely antiproliferative cytotoxic agent.
36
37 Rather, an effect on tumor angiogenesis seems to play a decisive role. Other Authors have
38
39 previously reported that sanguinarine is a potent antiangiogenic natural product, able to
40
41 suppress *in vitro* VEGF-induced endothelial cell migration, sprouting, and survival [27]. *In*
42
43 *vivo* studies confirmed its activity as a potent inhibitor of blood vessel formation in the mouse
44
45 Matrigel plug assay (the drug was incorporated into the Matrigel), and in the chicken
46
47 chorioallantoic membrane assay (the drug was air-dried on plastic discs then applied to the
48
49 CAM surface) [27]. To our knowledge, the present study is the first to report an effect of
50
51 sanguinarine as angiogenesis inhibitor, following systemic administration to experimental
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 animals. Moreover, Western analysis on A375 tumors showed a relevant reduction in AKT
2 activation in treated mice when compared to controls. Notably, this finding is in keeping with
3 previous findings reported by other Authors demonstrating, in *in vitro* models, that the
4 antiangiogenic effect of sanguinarine could occur partly through blocking the VEGF-
5 induced PI 3'-kinase/AKT activation, a pivotal event in angiogenesis signaling [27,28].
6
7

8
9 One mechanism by which VEGF-targeted therapy may be of benefit in cancer treatment is by
10 counteracting the up-regulation of VEGF expression following genotoxic stress induced by
11 chemotherapy or radiation therapy [29]. Notably, treatment of human melanoma cells with
12 dacarbazine caused an increase in secreted VEGF-A, and interleukin 8 (IL8) [30], and
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Acknowledgements

This study was supported in part by the Ministero Istruzione Università e Ricerca (Decreto No. 1587). Sanguinarine and Cheliritrine were donated by INDENA s.p.a.

Literature Cited

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 Version 2.0. Lyon, France: IARCPress; 2004.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. *CA Cancer J Clin* 2008; 58:71-96.
3. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. *Nature* 2007; 445:851-7.
4. Tarhini AA & Agarwala S S. Cutaneous melanoma: available therapy for metastatic disease. *Dermatol Ther* 2006; 19:19–25.
5. Kirkwood JM, Moschos S, & Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines vaccines, and combinations. *Clinical Cancer Res* 2006; 12:2331s–2336s.
6. Mukherjee AK, Basu S, Sarkar N and Ghosh AC. Advances in cancer therapy with plant based natural products. *Current Med Chem* 2001; 8:1467–1486.
7. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. *Clinical Cancer Res* 2000; 6:1524–1528.
8. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. *Clinical Cancer Res* 2000; 6:737-42.
9. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. *Mol Cancer Ther* 2004; 3: 933–940.

10. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB.
Sanguinarine (pseudocheletrythrine) is a potent inhibitor of NF- κ B activation, I κ B α
phosphorylation, and degradation. *J Biol Chem* 1997; 272:30129-30134.
11. Ding Z, Tang SC, Weerasinghe P, Yang X, Pater A, Liepins A. The alkaloid sanguinarine
is effective against multidrug resistance in human cervical cells via bimodal cell death.
Biochem Pharmacol 2002; 63:1415–1421.
12. Serafim TL, Matos JA, Sardão VA, Pereira GC, Branco AF, Pereira SL, et al.
Sanguinarine cytotoxicity on mouse melanoma K1735-M2 cells-Nuclear vs.
mitochondrial effects. *Biochem Pharmacol* 2008; 76:1459-75.
13. Motulsky HJ and Ransnas LA. Fitting curves to data using nonlinear regression: a
practical and nonmathematical review. *FASEB J* 1987; 1:365–374.
14. Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, et al. Thiocolchicine
dimers: a novel class of topoisomerase-I inhibitors. *Biochem Pharmacol* 2005;69:113-21.
15. Pommier Y, Schwartz RE, Zwelling LA and Kohn KW. Effects of DNA intercalating
agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell
nuclei. *Biochemistry* 1985; 24:6406–6410.
16. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines
for the Welfare of Animals in Experimental Neoplasia (Second Edition). *Br J Cancer*
1998; 77:1-10.
17. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, et al. In vivo methods
for screening and preclinical testing. In Teicher BA (ed) *Anticancer Drug Development*
Guide. Humana Press, Totowa, New Jersey, 1997:75-99.
18. Gallo D, Zannoni GF, Martinelli E, Ferlini C, Fabrizi M, Riva A, et al. Estradiol and
phytoestrogens differently influence the rodent postmenopausal mammary gland.
Menopause 2006; 13:72-9.

19. Gallo D, Zannoni GF, De Stefano I, Mosca M, Ferlini C, Mantuano E, et al. Soy phytochemicals decrease nonsmall cell lung cancer growth in female athymic mice. *J Nutr* 2008;138:1360-4.
20. Passaniti A, Taylor RM, Pili R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab Invest* 1992; 67:519–528.
21. Maiti M, Nandi R and Chaudhuri K. Sanguinarine: a monofunctional intercalation alkaloids. *FEBS Lett* 1982; 142: 280–284.
22. Kaminsky V, Lin KW, Filyak Y, Stoika R. Differential effect of sanguinarine, chelerythrine and chelidonine on DNA damage and cell viability in primary mouse spleen cells and mouse leukemic cells. *Cell Biol Int* 2008; 32:271-7.
23. Malíková J, Zdarilová A, Hlobilková A, Ulrichová J. The effect of chelerythrine on cell growth, apoptosis, and cell cycle in human normal and cancer cells in comparison with sanguinarine. *Cell Biol Toxicol* 2006; 22:439-53.
24. Meier F, Schitteck B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. *Front Biosci* 2005; 10:2986-3001.
25. Han MH, Kim SO, Kim GY, Kwon TK, Choi BT, Lee WH, et al. Induction of apoptosis by sanguinarine in C6 rat glioblastoma cells is associated with the modulation of the Bcl-2 family and activation of caspases through downregulation of extracellular signal-regulated kinase and Akt. *Anticancer Drugs* 2007; 18:913-21.
26. Kim S, Lee TJ, Leem J, Choi KS, Park JW, Kwon TK. Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. *J Cell Biochem* 2008; 104:895-907.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
27. Eun JP, Koh GY. Suppression of angiogenesis by the plant alkaloid, sanguinarine. *Biochem Biophys Res Commun* 2004; 317:618-24.
28. Basini G, Bussolati S, Santini SE, Grasselli F. Sanguinarine inhibits VEGF-induced angiogenesis in a fibrin gel matrix. *Biofactors* 2007; 29:11-8.
29. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 2008; 8:579-91. Review.
30. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. *Mol Cancer Ther* 2003; 2:753-63.
31. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. *J Clin Oncol* 2004; 22:2092-100.

FIGURE LEGENDS

Figure 1 –Comet assay performed in isolated nuclei in the presence of the vehicle (Control, DMSO 0.1%), sanguinarine (0.1, 0.25, 0.5, 1, 2.5 and 5 μ M), chelerritrine (0.1, 0.25, 0.5, 1, 2.5 and 5 μ M), or H₂O₂ (50 μ M) as positive control. **(A)** Representative image of the experiment reported in the bar chart. **(B)** Bar chart showing the results of the % Tail DNA. This experiment was repeated three times with similar results. * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$ vs Control

Figure 2 (A) Agarose gel electrophoresis for a cell free DNA relaxation assay of a supercoiled pBluescript plasmid DNA, treated with the tested compounds from 2 to 30 min. Relaxed DNA topoisomers (rel) slowly migrate in the gel as compared to supercoiled DNA (sc). After 30 min the full DNA relaxation is obtained in control lanes (DMSO 0.5%). Sanguinarine and chelerritrine strongly inhibit the activity of Topoisomerase-I at 50 μ M; CPT was used as a positive control. **(B)** Representative image of the agarose gel electrophoresis for DNA unwinding assay. Several topoisomers of a DNA plasmid are noticeable in normal isotonic buffer (rel, Ctrl 15'), but when an intercalating agent is added to DNA the structure of DNA changes, and the number of topoisomers decreases, as occurred in the presence of sanguinarine and chelerritrine (50 μ M), with presence of supercoiled (sc) DNA. Ethidium Bromide was used as positive control. To confirm full relaxation of DNA, one sample was terminated with SDS after 75 min (Ctrl 75'). This experiment was repeated three times with similar results.

Figure 3 – **(A)** B16 melanoma 4A5 tumor growth, and **(B)** body weight, of female C57BL6 mice receiving 0 (control) or 5 mg/kg/day sanguinarine (means $\pm$ SEM, n=10/group); *different from control at that time, $p < 0.01$. **(C)** A375 xenograft growth, and **(D)** body weight

of female athymic mice receiving 0 (control) or 5 mg /kg/day sanguinarine (mean $\pm$ SEM, n=11-12/group at the start of the study. Data are reported until n=5/group); *different from control at that time, $p<0.05$. (E) Kaplan-Meier curves showing the tumor progression of female athymic mice with A375 xenografts (n=11-12/group). The end-point was tumor weight = 1000 mg. * = $p<0.05$ vs Control (Logrank test). By day 77 of the study, there were three tumor-free mice; these mice were no longer dosed, showing no evidence of tumor after a further treatment-free observation period of 60 days (i.e. day 137 of the study).

Figure 4 – (A) Representative immunohistochemical localization of Ki67, and **(B)** tumor proliferation, in A375 xenografts from female athymic mice receiving 0 (control), or 5 mg/kg/day sanguinarine (mean $\pm$ SEM, n=8 tumors/group). Magnification 20x. **(C, E)** Representative western blots, and **(D, F)** protein expression for p-p44/42MAPK/total-p44/42 MAPK and p-AKT/AKT, respectively, in A375 tumors from female athymic mice receiving 0 (control), or 5 mg/kg/day sanguinarine (mean $\pm$ SEM, n=8 tumors/group).

Figure 5 - Effects of sanguinarine on *in vivo* angiogenesis in the Matrigel plug assay. (A) Macroscopic evaluation of the Matrigel plugs. Angiogenic plugs appear red-orange with small curly vessels, non-angiogenic plugs appear translucent. **(B)** Hemoglobin content (g/dl) of the pellets in control and sanguinarine (5 mg/kg/day os)-treated mice. The box extend to the 25th and 75th percentiles; the horizontal bars indicate median values, and whiskers minimum and maximum values (n=10/group).

Figure 1

Figure 2**A** **B**

Figure 3

Figure 4

Figure 5

Preclinical *in vivo* antiproliferative and antiangiogenic effects of Sanguinarine in melanoma